We studied the adhesion properties of peripheral blood leukemic cells from 1 0 patients with adult T-cell leukemia (ATL) to endothelial cells to better understand the mechanism of leukemic cell infiltration. ATL cells expressed lymphocyte function-associated antigen-1 (LFA-1 ), but the expression of very late antigen-4 (VLA-4) and sialyl-Lewisx (SLex) was variable. They did not express sialyl-Lewis' (SLea). Cell adhesion assays, which were performed in nine patients, showed marked adhesion of ATL cells to in- 
cular addressin interactions, namely, LFA-1 with ICAM-1 and ICAM-2 (ICAMs), VLA-4 with VCAM-1, and the sialylated carbohydrates with E-selectin, have been identified as involved in studies using human umbilical vein endothelial cells (HUVEC).9r'o Under nonstatic conditions, L-selectin is also reported to participate in T-cell adhesion to HUVEC." Other pathways, such as the CD44-mediated pathway, have also been shown to be involved in T-cell adhesion to the high endothelial venules of lymph nodes.5 However, the significance of these interactions in pathologic states remains unclear.
The aim of the present study was to investigate the molecules involved in interactions between ATL cells and endothelial cells to increase our understanding of the mechanism involved in tissue invasion by ATL.
MATERIALS AND METHODS

Monoclonal antibodies (MoAbs).
Purified IgG MoAbs, antiTac (anti-CD25) and 2R-B (anti-interleukin [ILI-2 receptor /3 chain), were prepared as reported previ~usly.'~~" OKT4 (anti-CD4), OKT8 (anti-CDS), OKMl (antLCD1 Ib), OKlal (anti-HLA class-2), and X63 (control IgG) were obtained from the American Type Tissue Collection (Rockville, MD). 3G8 (anti-CD16) was a gift from Dr J.C. Unkele~s'~ (Mount Sinai Medical Center, New York, NY). HP2/1 (anti-CD49d, the 01 chain of VLA-4), 84H10 (anti-CD54, ICAM-I), and J-173 (anti-CD44) were purchased from Immunotech (Marseille, France). 3B7, 7A9 (anti-E-selectin) and 2G7 (anti-VCAM-I) were kindly provided by Dr W. Newman" (Otsuka America Pharmaceutical, Rockville, MD). 3B7 and 7A9 were shown to be equally effective in blocking E-selectin-mediated leukocyte adhesion to HUVEC. Leu-S(anti-LECAM-I), Leu-18(anti-CD45RA), UCHLl (anti-CD45RO). and B1 (anti-CD2O) were obtained from Becton-Dickinson Immunocytometry Systems (Mountain View, CA), Nichirei (Tokyo, Japan), and Coulter Immunology (Hialeah, FL), respectively. All of the MoAbs listed above were purified IgG antibodies. MHM23 (anti-CD18, the p chain of LFA-1 and Mac-I), MHM24 (anti-CDI la, the 01 chain of LFA-I), and TUK4 (anti-CD14) were purchased from Dakopatts (Glostrup, Denmark) as hybridoma culture supernatants. Two anti-sialyl Lewis" MoAbs (2D3 [a purified IgM antibody] and IH4 [a purified IgG, antibody]16), as well as two anti-sialyl Lewis" MoAbs (FH6 [a purified IgM antibody]" and SNH3 [an IgM antibody, hybridoma culture supernatant]'*) were gifts from Dr R. Kannagi (Aichi Cancer Research Institute, Nagoya, Japan). Another anti-sialyl Lewis" mAb (CSLEX-I [an IgM antibody, ascitic fluid]'') were ob-tained from the American Tissue Culture Collection. For immunohistochemical staining, BBA 5 and BBA 1 (British Bio-technology, Oxon, UK) were also used as anti-VCAM-1 and anti-E-selectin MoAbs, respectively.
Lymphocyte preparation. Peripheral blood leukemic cells from I O ATL patients were studied. The diagnosis of ATL was made based on the clinical features, hematologic findings (including the characteristic surface expression of CD25; Tac antigen), serum antibodies against HTLV-I , and, in some cases, monoclonal HTLV-1 provirus integration into leukemic cell DNA. Peripheral blood mononuclear cells were isolated by Ficoll-Conray density gradient centrifugation. In all cases, the percentage of leukemic cells determined by both CD4+ and CD25' cells and used for each assay was greater than 90%. In cases where the initial purity of the isolated leukemic cells was low, negative immunoselection with magnetic beads was performed. To purify the ATL cells, peripheral blood mononuclear cells were incubated for 30 minutes at 4°C with a cocktail of MoAbs against CD8, CDl Ib, CD14, CD16, and CD20. After two washes, immunomagnetic beads (Dynabeads M-450; Dynal, Oslo, Norway) were added and incubated for 1 hour at 4°C to rosette non-ATL cells, which were then removed with a Dynal magnetic particle concentrator. The proportion of the CD4+ cells and CD25+ cells in the negatively selected cells was greater than 99% and 95%, respectively. Since the ATLcells from case no. 9 were positive for CD8, as well as CD4, no MoAb against CD8 was used when purifying cells from this patient and the purity of ATL cells obtained also exceeded 95%. In some experiments, cryopreserved ATL cells, thawed just before each assay, were used. Resting CD4+CD45RO+ T cells from healthy volunteers were purified by the same negative immunoselection technique using additional MoAbs against HLA-DR and CD45RA. The percentage ofthe resting CD4+CD45RO* T cells was approximately 90%. Lymphocytes prepared in this manner were labeled with 51Cr and used for the adhesion assays. To obtain acutely activated T cells, IO ng/mL of phorbol myristate acetate (PMA; Sigma Chemical, St Louis, MO) was added to the cell suspension during the last 30 minutes of 51Cr labeling.
Endothelial cells. HUVEC were isolated by collagenase digestion according to the procedure of Jaffe et al." In brief, umbilical cords obtained at normal deliveries were washed with 70% ethanol. The umbilical veins were rinsed with phosphate-buffered saline (PBS) and treated with 0.1% collagenase/PBS for 30 minutes at room temperature. Subsequently, the collagenase suspension was harvested and HUVEC were obtained by centrifugation. The pelleted cells were suspended in M 199 medium (GIBCO Laboratories, Grand Island, NY) containing 15% fetal calf serum (FCS; Irvine Scientific, Santa Anna, CA) and were incubated in a gelatin-coated flask (Coming Glass Works, Corning, NY). After incubation for 6 hours at 37"C, the endothelial cells were washed and cultured in MI99 medium supplemented with 15% FCS, 90 & n L porcine intestinal heparin (Sigma), 30 pg/mL endothelial cell growth supplement (Collaborative Research, Bedford, MA), and antibiotics. HU-VEC monolayers were then maintained in M 199 medium containing the same additives and cells in the second through the fourth passages were used in the subsequent assays. The endothelial nature of the cells was confirmed by examining their morphology at confluence and by detecting the expression of von Willebrand factor using an immunofluorescence assay. Weak expression of ICAM-1 and no expression of VCAM-1 and E-selectin on the resting HU-VEC was demonstrated by radioimmunoassay and flow cytometry, while the induction of marked expression of these three molecules was noted after activation with 10 ng/mL of IL-lp.
Cell adhesion assay. HUVEC were plated onto gelatin-coated 24-or 96-well plates (Corning) and cultured until confluence with or without prior exposure to I O ng/mL of IL-1P (Otsuka Pharmaceutical, Tokyo, Japan) for 4 hours at 37°C. The cells were then rinsed twice with RPMI 1640 (GIBCO) supplemented with 10% FCS. Either 3 X IO5 "Cr-labeled lymphocytes in a final volume of 300 pL (for the 24-well plates) or 6 X IO4 cells in a final volume of 60 pL (for the 96-well plates) were added to each well. After being left for 20 minutes at 3 7 T , the HUVEC were washed gently three times with prewarmed RPMI/lO% FCS medium, and the remaining adherent cells were lysed with I% nonidet P-40 in PBS. One half of this volume was counted in a gamma-counter. To examine the effect of various MoAbs on lymphocyte adhesion to the HUVEC, IL-I-treated or untreated HUVEC and "Cr-labeled T cells were incubated separately with a saturating concentration (final concentration, 10 pg/mL) of each MoAb for 30 minutes at room temperature. Lymphocytes were then added to each well containing HU-VEC and MoAbs. All experiments were performed in duplicate or triplicate. For some experiments, confluent monolayers of HUVEC on plastic tissue culture dishes (Coming) were exposed to 10 ng/mL of IL-1P for 4 hours at 37°C. After washing out the IL-1, lymphocytes ( 1 X IO' cells in a final volume of 10 mL) were added and incubated with the HUVEC for 20 minutes at 37OC. The nonadherent cells were then removed by gentle washing with prewarmed RPMI/10% FCS, and the remaining adherent cells were harvested by rinsing twice with PBS containing 5 mmol/L EDTA. After the last rinse with PBS/EDTA, few lymphocytes were detected microscopically.
Flow cytometric analysis. Cells (2 X IO5 in 20 wL) were stained with a saturating amount of unconjugated MoAb followed by incubation with the fluorescein isothiocyanate (FITC)-conjugated (Fab'), fraction of goat antimouse IgG (Tago, Burlingame, CA) or rabbit antimouse IgM (Zymed, San Francisco, CA). When contaminating non-ATL cells were thought likely to influence the results, further incubation was performed with a phycoerythrin-conjugated IL-2 receptor antibody (CD25, Becton-Dickinson Immunocytometry Systems) after all unoccupied binding sites of the secondary antibodies were blocked with normal mouse serum. The stained cells were analyzed using a FACScan (Becton-Dickinson Immunocytometry Systems), and when dual-color analysis was performed, lymphocytes were gated based on the expression of CD25. The quantitation of the cell populations described in this report was based on cutoff points designed to exclude 95% or more of the negative control population.
Immunohistochemistry. Skin tissue specimens were obtained from cases no. 1 and I O for immunohistochemical examination. The specimens were divided into two pieces, one fixed in formalin and the other frozen at -80°C. Then, serial, acetone-fixed, air-dried cryostat sections (3 to 5 pm) were prepared from the snap-frozen tissue specimens and stained using a HISTOSET Immunoperoxidase Staining Kit (Ortho Diagnostic Systems, Raritan, NJ) according to the manufacturer's directions.
RESULTS
Expression of adhesion molecules on ATL cells. Table 1 shows the clinical profiles of the patients examined. Nine of 10 patients had evidence of organ involvement, which was diagnosed mainly from the clinical findings and was histologically confirmed in cases no. 1 and 10 (skin), as well as case no. 7 (lung). ATL cells were positive for CD4, CD25, and the p chain of the IL-2 receptor in all patients (data not shown). CD45RO was also positive, except in case no. 8, in which 70% of the ATL cells were CD45RO-. Therefore, we compared the ATL cells with normal CD4+CD45RO+ memory T cells in the following experiments. ATL cells from all For personal use only. on September 24, 2017. by guest www.bloodjournal.org From cases expressed CDl la (LFA-l), and its fluorescence intensity was equivalent to that of normal memory T cells. The percentage of CD49d' (VLA-4) cells and its fluorescence intensity were not different between normal memory T cells and ATL cells from six patients (cases no. 2, 3, 4,6, 7, and 9). VLA-4 was not expressed in two patients (cases no. 8 and 10). In the remaining two patients (case no. I and 5), a few ATL cells were weakly positive for VLA-4. The expression of LECAM-1 also varied considerably. In addition, the results of the study of sialyl-Lewis" (SLex) expression seemed more complicated. We used three different MoAbs (FH6, SNH3, and CSLEX-I) to detect its expression. A minor proportion of the normal memory T cells were weakly positive, and the percentage of SLex+ cells was similar irrespective of the MoAb used. However, in the case of ATL cells, the reactivity pattern vaned with each MoAb used. For example, SNH3 moderately stained the ATL cells of case no. 7, whereas neither FH6 nor CSLEX-1 did. However, it is noteworthy that the increased expression of SLex was demonstrated in eight of 10 ATL patients (cases no. 2, 3, 5, 6, 7, 8, 9, and 10). The expression of sialyl-Lewis" (SLea) was tested in all patients except case no. 3, and normal memory T cells from three volunteers using two different mAbs (2D3 and 1H4), but these MoAbs did not react with any of the cells (data not shown). The ATL cells were also analyzed for their capacity to adhere to resting and IL-1 -stimulated HUVEC. As shown in Table 2 , adhesion to resting HUVEC was observed in two patients (cases no. 8 and 9). In contrast, a considerable proportion (17.4% to 74.3%) of the ATL cells showed adhesion to IL-1 -stimulated HU-VEC in nine patients examined. Blocking studies were performed in eight patients (cases no. 2 to 9) and showed that Adhesion ofATL cells to HUVEC.
the addition of anti-VCAM-I MoAb (2G7) or anti-VLA-4 MoAb (HP2/1) inhibited ATL cell adhesion to IL-1-activated HUVEC in five patients (cases no. 2, 3,4, 6, and 7). We had used the anti-VCAM-I MoAb for adhesion blocking studies until it was reported that there might be non-VCAM-I counter-receptors for VLA-4." In cases no. 5 and 8, most of the ATL cells lacked VLA-4 expression, which appeared to be the reason for the failure of adhesion inhibition by the anti-VLA-4 or anti-VCAM-1 MoAbs. The addition of anti-E-selectin MoAbs (3B7 and/or 7A9) also reduced the adhesion of ATL cells to activated HUVEC in six patients (cases no. 2, 3, 5, 6 , 7, and 8) . In case no. 4, the combination of an anti-VCAM-1 MoAb and an anti-E-selectin MoAb inhibited ATL cell adhesion more strongly than addition of the anti-VCAM-1 MoAb alone, indicating that an E-selectin-mediated adhesion pathway was also present. In case no. 9, the addition of an anti-E-selectin MoAb to the combination of anti-LFA-1 and anti-VLA-4 MoAbs dramatically decreased ATL cell adhesion to IL-1-activated HUVEC.
Thus, an E-selectin-mediated pathway was detected in all patients tested. The degree of adhesion inhibition by anti-VCAM-1 or anti-VLA-4 MoAbs and that by anti-E-selectin MoAb were not consistent in each case. In other words, the inhibition by anti-VCAM-1 or anti-VLA-4 MoAbs was more marked than by anti-E-selectin MoAb in cases no. 4, 6, and 7, and vice versa in cases no. 2, 3, 5, and 8.
In contrast, the addition of an anti-LFA-1 MoAb (MHM23) alone had no effect on ATL cell adhesion to resting or IL-I-activated HUVEC. In cases no. 6 and 7, the combination of anti-VCAM-1 and anti-E-selectin MoAbs inhibited ATL cell adhesion with IL-1-activated HUVEC almost completely, and the addition of the anti-LFA-1 MoAb to this combination of MoAbs had no effect on ATL Table 2 ). Considering that VLA-4 expression was hardly detectable in this patient, LFA-1-mediated adhesion appeared to occur. In case no. 9, although anti-LFA-1 or anti-VLA-4 MoAbs did not diminish cell adhesion when either one was added alone, the combination of these two MoAbs decreased cell adhesion ( Table 2) .
To investigate further the role of LFA-1-mediated ATL cell adhesion to HUVEC, freshly isolated ATL cells were modified by short-term culture or by exposure to PMA. In case no. 5, the adhesion of cultured ATL cells to IL-1 -activated HUVEC was clearly inhibited by the addition of anti-LFA-I MoAb, although this did not occur with freshly isolated cells (Fig I) . In case no. 7, PMA-stimulated ATL cells showed adhesion to resting HUVEC and this adhesion was almost completely inhibited by the anti-LFA-I MoAb. PMA-stimulated ATL cells also adhered well to IL-l-activated HUVEC, and the sole addition of the anti-LFA-1 MoAb slightly inhibited this adhesion (Fig 1) . These results suggested that the LFA-1 -mediated adhesion pathway was not fully functional in freshly isolated ATL cells.
As described above, the ATL patients displayed considerable variability in the adhesion characteristics. Therefore, it seemed important to know whether reproducible results could be obtained from the same patient when examined at different times. In case no. 5, we obtained blood samples at two different times with a 1-month interval before the administration of anticancer drugs, and found that the surface expression of adhesion molecules did not differ between these two samples (data not shown). The ATL cells were cryopreserved and thawed just before assay, but the freezing and thawing procedures did not affect cell viability or surface phenotype (data not shown). As shown in Fig 2, the frozen and thawed cells displayed a somewhat increased adhesion to resting HUVEC, which could not be blocked by the anti-LFA-1 MoAb. Adhesion to IL-1-activated HU-VEC occurred via E-selectin-mediated pathway on both occasions, and VLA-4-or LFA-1 -mediated adhesion were not observed despite different level of cell adhesion, which still remained after the blocking by any combination of MoAbs tested. For personal use only. on September 24, 2017. by guest www.bloodjournal.org From LFA-1 was uniformly observed and there were no differences in the expression of LFA-1 between the cells with or without adherence to IL-1 -activated HUVEC (data not shown).
In cases no. 1 and 10, biopsy samples of skin lesions were examined to determine the expression of adhesion molecules on the endothelial cells. Sections from formalin-fixed specimens were stained with hematoxylin/eosin, which showed the diffuse infiltration of atypical lymphocytes into the upper dermis and focal infiltration into the deep dermis in both patients (data not shown). Immunohistochemical staining of cryostat sections showed that the infiltrating lymphocytes were CD4' (data not shown) and CD25' (Fig SA and D) , indicating that they were ATL cells. Some ofthe small vessels in the dermis were strongly stained with an anti-E-selectin mAb, BBA 1 (Fig 5C and F) , and more of the vessels were also stained with the anti-ICAM-1 MoAb, 84H10 (Fig 5B and  E) . The infiltrating lymphocytes were also stained with 84H IO in both patients, which was compatible with the flow cytometric findings (data not shown). In contrast, none of the vessels were reactive with the anti-VCAM-1 MoAb, BBA 5, in either patient (data not shown).
Immunohistochemical examination.
DISCUSSION
The adhesion of ATL cells to endothelial cells is apparently one of the critical events in leukemic cell infiltration Adhesion of normal CD4+CD45RO+ T cells. We next examined the adhesion characteristics of resting and PMAactivated CD4+CD45RO+ memory T cells from healthy individuals (Fig 3) . Minimal adhesion of resting memory T cells to resting HUVEC was observed despite the increase of adhesion to IL-1 -activated HUVEC. Adhesion of resting memory T cells to IL-1-activated HUVEC was inhibited by anti-LFA-1, anti-VCAM-1, and anti-E-selectin MoAbs, when added alone or in combination. The inhibition of adhesion by anti-VLA-4 or anti-E-selectin MoAbs was more profound than that by the anti-LFA-l MoAb, indicating that the VLA-4-and E-selectin-mediated pathways were more important in the adhesion of resting memory T cells to IL-I -activated HUVEC. PMA-stimulated memory T cells showed significant adhesion to resting HUVEC, which was markedly inhibited by the anti-LFA-I MoAb. A higher proportion of the PMA-stimulated memory T cells than the resting cells showed adhesion to IL-1-activated HUVEC. Adhesion blocking studies indicated that anti-LFA-I , anti-VLA-4, and anti-E-selectin MoAbs were all effective in inhibiting cell adhesion to IL-1 -activated HUVEC.
Expression of adhesion molecules on ATL cells with or without adherence to HUVEC. In cases no. I, 2, and 5, we compared the cell surface expression of adhesion molecules in the cells that did and did not adhere to IL-I-activated HUVEC (Fig 4) . In case no. I, the adhesion blocking study with cryopreserved and thawed ATL cells showed that the E-selectin-mediated adhesion pathway was predominant, and that LFA-1 -and VLA-4-mediated adhesion did not occur (data not shown). However, we could detect only weak expression of SLex on the cells adherent to HUVEC. There was no difference in VLA-4 expression between cells with or without adherence to HUVEC. In case no. 2, the VCAM-I-mediated pathway played an important role in the ATL cell adhesion to activated HUVEC, and in case no. 5, the E-selectin-mediated pathway was predominant. There was a slight increase of SLex+ cells among the adherent population of both patients, although a significant proportion of the adherent cells were SLex-. The expression of into various organs. We used HUVEC monolayers to investigate the molecules involved in ATL cell-endothelial cell interactions, because such monolayers can be prepared easily and the adhesion molecules on HUVEC have been intensively studied.
The ATL cells from nine patients showed adhesion to IL-1-activated HUVEC, but adhesion to resting HUVEC was seen in only two cases. The blocking studies were performed using freshly isolated ATL cells from eight patients, and showed that VLA-4 (or VCAM-1) and E-selectin mediated the adhesion ofATL cells to IL-I-activated HUVEC (Table 2) . Despite its uniform expression on ATL cells, the contribution of LFA-I to cell adhesion was slight or nonexistent. Although the adhesion characteristics of ATL cells, as well as their expression of adhesion molecules, differed considerably from patient to patient, the assay results were shown to be almost identical in the same patient at different times (Fig 2) . E-selectin-mediated adhesion was detected in all of the assessable patients, which suggests that E-selectin plays a pivotal role in ATL cell/endothelial cell interactions. The finding that E-selectin was expressed on the endothelial cells in cutaneous ATL lesions also supports this notion (Fig   5) .
It seems unlikely that VLA-4 plays a major role in the adhesion of ATL cells to endothelial cells in vivo because of the following findings, even though some VLA-4-or VCAM-1 -mediated adhesion to IL-1 -activated HUVEC was detectable in many patients. First, VLA-4 was not expressed consistently on ATL cells. In fact, organ infiltration was detected in all four patients in whom the expression of VLA-4 was not demonstrated or was observed in only a small proportion of the ATL cells (Table 1) . Second, VLA-4+ cells were not concentrated in the cell population adherent to HUVEC (Fig 4) . Finally, the immunohistochemical studies of cases no. I and 10 did not detect VCAM-1 molecules on the endothelial cells at the skin where ATL cells infiltrated.
The LFA-I expressed on the freshly isolated ATL cells did not contribute to adhesion to HUVEC in cases no. 6 and 7, although a slight to moderate contribution was observed in cases no. 8 and 9 ( Table 2 ). The results obtained in cases no. 5 and 7 (Fig 1) indicated that the LFA-1 molecules expressed on freshly isolated ATL cells did not function properly and that some stimulus is needed for them to fully function as ligands of ICAMs.
E-selectin was first recognized as an endothelial cell surface antigen induced by cytokines and endotoxins:2 and its expression is known to be limited to the venous endothelium at sites of i n f l a m m a t i~n .~~ In contrast to its wide distribution in acute inflammation, the expression of E-selectin is normally limited to the venous endothelium of the skin in chronic inflammati~n.'~ Short-term skin organ culture has shown that E-selectin is readily expressed on endothelial cells in vitro,24 which suggests that its expression on the venous endothelium is easily inducible in the skin. It was reported that ATL cells produce several kinds of cytokines, including IL-1 .25,26 Thus, the frequent skin involvement in ATL might be partly explained through the production of For personal use only. on September 24, 2017. by guest www.bloodjournal.org From cytokines by ATL cells, which then induce the E-selectin expression on the venous endothelium in the skin and subsequent E-selectin-mediated adhesion of ATL cells.
Several sialylated carbohydrates are known to be ligands for E -~e l e c t i n . '~.~~-~~ The glycoproteins containing SLex are thought to be the ligands of E-selectin in ne~trophils.~~.'~ SLea and SLex have been reported to be the counter-receptors for E-selectin binding in some cancer cell lines that adhere to IL-1 -activated HUVEC via an E-selectin-mediated p a t h~a y . '~.~~ The expression of SLea on ATL cells was not detected in our nine patients, and SLex was not consistently detectable on the ATL cells (Table 1) . Significant E-selectin-mediated adhesion to HUVEC was observed in case no. 4, although only a low percentage of ATL cells was positive for SLex (Tables 1 and 2 ). The population of SLex' cells was not increased among the ATL cells adherent to HUVEC in cases no. 1 and 5, despite the predominant role of the E-selectin-mediated pathway in ATL cell-HUVEC adhesion (Table 2 and Fig 4) . There seems to be two possibilities regarding the controversial results: ( 1) SLex expressed on ATL cells was not fully recognized by the MoAbs used in this study. A previous study has demonstrated the different reactivity of anti-SLex MoAbs with leukemic cell lines." Examination using other MoAbs may detect SLex epitope on ATL cells. (2) A carbohydrate other than SLex or SLea is the ligand for E-selectin on ATL cells. Recent reports have indicated that the cutaneous lympho- cyte antigen defined by HECA-452 MoAb, which is another sialylated carbohydrate antigen and closely associated with SLex, is E-selectin ligand for memory T cells.30 The E-selectin ligand for ATL cells may be this cutaneous lymphocyte antigen, since the majority of ATL cells have the same phenotype as memory T cells. In any case, the ligand for E-selectin appears to be different from that of neutrophils.
The majority of ATL cells express CD25 (Tac antigen) and HLA-DR. 4 In addition, the ATL cells from 20% to 3090 of patients proliferate in response to IL-2 and/or IL-4 without any other ~t i m u l i .~.~' These observations indicate that ATL cells share some of the characteristics of activated T cells. Because the adhesion of ATL cells to IL-I-activated HUVEC was mostly mediated through E-selectin and partly through VLA-4, they resembled resting CD4+CD45RO+ memory T cells, rather than PMA-stimulated memory T cells in this respect. The major difference in the adhesion properties between ATL cells and PMA-stimulated memory T cells was the inability of the LFA-1 molecules on ATL cells to effectively bind with ICAMs. Thus, the activated status of ATL cells appears to be different from that of PMA-stimulated memory T cells.
In neutrophils, the interaction of SLex/E-selectin is thought to be responsible for leukocyte trapping, and the interaction of LFA-1 and Mac-1 /ICAMs are considered to be the key events in their firm attachment and transendothelial m i g r a t i~n .~,~~.~' In T cells. the molecules responsible for For personal use only. on September 24, 2017. by guest www.bloodjournal.org From the transmigration have been reported to be LFA-I and VLA-4.34 One can then ask what molecules are responsible for the transmigration of ATL cells, especially those which do not express VLA-4 molecules. There seem three possibilities on this issue. First, LFA-1 molecules on ATL cells would acquire the ability to bind to ICAMs in the course of cell adhesion through a mechanism that was not reproduced using HUVEC as the endothelial cells. The induction of ICAM-1, as well as E-selectin expression, on the endothelial cells in ATL skin lesions supports this idea. Second, E-selectin may play a predominant role in both the adhesion and transendothelial migration of ATL cells. Third, there may be other as yet unidentified molecules that are responsible for ATL cell transmigration. Further studies in this area should help to elucidate the mechanism of ATL cell infiltration and perhaps allow the development of new therapeutic approaches to prevent it.
